CRVS: Heavy Short Bets Meet Bullish Analyst Consensus Before Monday Print

Corvus Pharmaceuticals heads into its August 4 earnings report with nearly a quarter of its free float sold short — one of the more charged setups in small-cap biotech right now.

Short sellers hold 23.9% of CRVS's free float, a level that has barely budged over the past month but has eased roughly 4.4% week-on-week as some bears trimmed positions. Days to cover is a lengthy 12.6 sessions, meaning any sharp move higher could force a disorderly unwind. The borrow market, however, does not yet show signs of stress. Availability runs at 131% — more than one share available for every share already borrowed — and cost to borrow is just 0.47%, barely changed over the past week. That tells a story of a heavily shorted stock where new short positions remain easy and cheap to establish. Options traders are not particularly worried either: the put/call ratio of 0.26 is essentially flat to its 20-day average of 0.255, with a z-score near zero. The stock itself has drifted down 11% over the past month to $13.26, though it clawed back about 1.5% over the past week. The ORTEX short score of 79.2 places the stock firmly in high-conviction bearish territory, even as that score has edged down from above 80 just two weeks ago.

The bull and bear cases are clearly drawn, and analyst sentiment sits decisively on the bullish side. Seven buy-equivalent ratings and a consensus mean target of $33.14 imply roughly 150% upside from current levels — though that gap underscores how much clinical execution the market is demanding before it closes. Goldman Sachs initiated at Buy in April with a $40 target, and Jefferies earlier this year lifted its target to $42. Bulls point to positive Phase 1b/2 data for lead candidate soquelitinib in atopic dermatitis and the potential for the drug to become a leading oral treatment in immune-mediated diseases, with pipeline value estimated by some analysts north of $3 billion. Bears counter that the company operates with a single-asset pipeline, that clinical-stage biotech cash burn is relentless, and that competition in inflammatory and oncology indications is intensifying. The negative PE and EV/EBITDA multiples reflect a pre-revenue company entirely dependent on trial outcomes.

Institutional ownership adds an interesting layer to the setup. OrbiMed Advisors, historically a significant holder, added over 1.4 million shares in the most recent filing period but also sold nearly 1.2 million shares back in June 2025 at much lower prices — a pattern of active management rather than passive accumulation. More recently, T. Rowe Price, Wellington Management, and State Street all added materially in the latest reported quarter, signalling that large institutions are still building exposure rather than trimming. CEO Richard Miller purchased shares on the open market in May at around $12, a modest signal of internal confidence at levels close to where the stock trades now. Correlated peers were broadly weaker on the day and over the week — IMNM, RGNX, and IMVT all fell on Friday — suggesting the small-cap biotech group overall lacks a positive tailwind heading into the session.

The August 4 print will ultimately test whether soquelitinib's clinical progress — and any updated guidance on cash runway — is sufficient to justify the wide gap between where the stock trades and what the bulls believe it is worth.